Efficacy of combination therapy of interferon-α with ursodeoxycholic acid in chronic hepatitis C: A randomized controlled clinical trial
Abstract The efficacy of interferon-α therapy in the treatment of chronic hepatitis C is still limited. A combination therapy of interferon-α with ursodeoxycholic acid (UDCA) was tested for its efficacy in the treatment of chronic hepatitis C by a randomized controlled study. Eighty consecutive Japa...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1997 |
|---|
| Umfang: |
7 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Journal of gastroenterology - 1994, 32(1997) vom: Jan., Seite 56-62 |
| Übergeordnetes Werk: |
volume:32 ; year:1997 ; month:01 ; pages:56-62 ; extent:7 |
| Links: |
|---|
| Katalog-ID: |
NLEJ207620601 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ207620601 | ||
| 003 | DE-627 | ||
| 005 | 20210706233236.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070528s1997 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ207620601 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Efficacy of combination therapy of interferon-α with ursodeoxycholic acid in chronic hepatitis C: A randomized controlled clinical trial |
| 264 | 1 | |c 1997 | |
| 300 | |a 7 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Abstract The efficacy of interferon-α therapy in the treatment of chronic hepatitis C is still limited. A combination therapy of interferon-α with ursodeoxycholic acid (UDCA) was tested for its efficacy in the treatment of chronic hepatitis C by a randomized controlled study. Eighty consecutive Japanese patients with chronic hepatitis C were randomly divided into two groups: one group was treated with interferon-α (group A,n=40) and the other with a combination of interferon-α and UDCA (group B,n=40). In both groups, human interferon-α (6 million units per day) was intramuscularly injected daily for 2 weeks and then three times a week for 22 weeks: this 24-week period was followed by 24 weeks of observation. In group B, UDCA was also administered, daily at a dose of 600mg orally, from the beginning of the interferon therapy and administration was continued for 48 weeks. The rates for ALT normalization and clearance of hepatitis C virus (HCV) viremia at the end of the 24-week interferon therapy were similar for groups A and B (58% vs 60% and 55% vs 48%, respectively). At the end of the 24-week follow-up, the sustained normalization rates for ALT levels for the two groups were not different (35% vs 43%), while the rate of clearance was higher in group B (40%) than in group A (23%), but the difference was not significant (P=0.14). The sustained complete response, i.e., HCV RNA negativity at the end of the follow-up, as well as the maintenance of ALT normalization during the follow-up period, was more frequent in group B (38%) than in group A (18%) although the difference was not significantP=0.08). The rate of HCV reactivation after interferon was discontinued was significantly lower in group B (16%) than in group A (59%) (P<0.01). Although this combination therapy did not lead to a sufficiently sustained complete response, it could serve as adjuvant antiviral therapy when a suitable dosage and administration period are determined. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Kiso, Shinichi |4 oth | |
| 700 | 1 | |a Kawata, Sumio |4 oth | |
| 700 | 1 | |a Tamura, Shinji |4 oth | |
| 700 | 1 | |a Imai, Yasuharu |4 oth | |
| 700 | 1 | |a Inui, Yoshiaki |4 oth | |
| 700 | 1 | |a Nagase, Toshihiko |4 oth | |
| 700 | 1 | |a Maeda, Yuichi |4 oth | |
| 700 | 1 | |a Yamasaki, Eiji |4 oth | |
| 700 | 1 | |a Tsushima, Hirofumi |4 oth | |
| 700 | 1 | |a Igura, Takumi |4 oth | |
| 700 | 1 | |a Himeno, Seiichi |4 oth | |
| 700 | 1 | |a Seki, Kouichi |4 oth | |
| 700 | 1 | |a Matsuzawa, Yuji |4 oth | |
| 773 | 0 | 8 | |i in |t Journal of gastroenterology |d 1994 |g 32(1997) vom: Jan., Seite 56-62 |w (DE-627)NLEJ188987215 |w (DE-600)1473159-9 |x 1435-5922 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:1997 |g month:01 |g pages:56-62 |g extent:7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/BF01213297 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 1997 |c 1 |h 56-62 |g 7 | ||
| matchkey_str |
article:14355922:1997----::fiayfobntoteayfnefrnihroexcoiaiicrnceaiicrn |
|---|---|
| hierarchy_sort_str |
1997 |
| publishDate |
1997 |
| allfields |
(DE-627)NLEJ207620601 DE-627 ger DE-627 rakwb eng Efficacy of combination therapy of interferon-α with ursodeoxycholic acid in chronic hepatitis C: A randomized controlled clinical trial 1997 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract The efficacy of interferon-α therapy in the treatment of chronic hepatitis C is still limited. A combination therapy of interferon-α with ursodeoxycholic acid (UDCA) was tested for its efficacy in the treatment of chronic hepatitis C by a randomized controlled study. Eighty consecutive Japanese patients with chronic hepatitis C were randomly divided into two groups: one group was treated with interferon-α (group A,n=40) and the other with a combination of interferon-α and UDCA (group B,n=40). In both groups, human interferon-α (6 million units per day) was intramuscularly injected daily for 2 weeks and then three times a week for 22 weeks: this 24-week period was followed by 24 weeks of observation. In group B, UDCA was also administered, daily at a dose of 600mg orally, from the beginning of the interferon therapy and administration was continued for 48 weeks. The rates for ALT normalization and clearance of hepatitis C virus (HCV) viremia at the end of the 24-week interferon therapy were similar for groups A and B (58% vs 60% and 55% vs 48%, respectively). At the end of the 24-week follow-up, the sustained normalization rates for ALT levels for the two groups were not different (35% vs 43%), while the rate of clearance was higher in group B (40%) than in group A (23%), but the difference was not significant (P=0.14). The sustained complete response, i.e., HCV RNA negativity at the end of the follow-up, as well as the maintenance of ALT normalization during the follow-up period, was more frequent in group B (38%) than in group A (18%) although the difference was not significantP=0.08). The rate of HCV reactivation after interferon was discontinued was significantly lower in group B (16%) than in group A (59%) (P<0.01). Although this combination therapy did not lead to a sufficiently sustained complete response, it could serve as adjuvant antiviral therapy when a suitable dosage and administration period are determined. Springer Online Journal Archives 1860-2002 Kiso, Shinichi oth Kawata, Sumio oth Tamura, Shinji oth Imai, Yasuharu oth Inui, Yoshiaki oth Nagase, Toshihiko oth Maeda, Yuichi oth Yamasaki, Eiji oth Tsushima, Hirofumi oth Igura, Takumi oth Himeno, Seiichi oth Seki, Kouichi oth Matsuzawa, Yuji oth in Journal of gastroenterology 1994 32(1997) vom: Jan., Seite 56-62 (DE-627)NLEJ188987215 (DE-600)1473159-9 1435-5922 nnns volume:32 year:1997 month:01 pages:56-62 extent:7 http://dx.doi.org/10.1007/BF01213297 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 32 1997 1 56-62 7 |
| spelling |
(DE-627)NLEJ207620601 DE-627 ger DE-627 rakwb eng Efficacy of combination therapy of interferon-α with ursodeoxycholic acid in chronic hepatitis C: A randomized controlled clinical trial 1997 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract The efficacy of interferon-α therapy in the treatment of chronic hepatitis C is still limited. A combination therapy of interferon-α with ursodeoxycholic acid (UDCA) was tested for its efficacy in the treatment of chronic hepatitis C by a randomized controlled study. Eighty consecutive Japanese patients with chronic hepatitis C were randomly divided into two groups: one group was treated with interferon-α (group A,n=40) and the other with a combination of interferon-α and UDCA (group B,n=40). In both groups, human interferon-α (6 million units per day) was intramuscularly injected daily for 2 weeks and then three times a week for 22 weeks: this 24-week period was followed by 24 weeks of observation. In group B, UDCA was also administered, daily at a dose of 600mg orally, from the beginning of the interferon therapy and administration was continued for 48 weeks. The rates for ALT normalization and clearance of hepatitis C virus (HCV) viremia at the end of the 24-week interferon therapy were similar for groups A and B (58% vs 60% and 55% vs 48%, respectively). At the end of the 24-week follow-up, the sustained normalization rates for ALT levels for the two groups were not different (35% vs 43%), while the rate of clearance was higher in group B (40%) than in group A (23%), but the difference was not significant (P=0.14). The sustained complete response, i.e., HCV RNA negativity at the end of the follow-up, as well as the maintenance of ALT normalization during the follow-up period, was more frequent in group B (38%) than in group A (18%) although the difference was not significantP=0.08). The rate of HCV reactivation after interferon was discontinued was significantly lower in group B (16%) than in group A (59%) (P<0.01). Although this combination therapy did not lead to a sufficiently sustained complete response, it could serve as adjuvant antiviral therapy when a suitable dosage and administration period are determined. Springer Online Journal Archives 1860-2002 Kiso, Shinichi oth Kawata, Sumio oth Tamura, Shinji oth Imai, Yasuharu oth Inui, Yoshiaki oth Nagase, Toshihiko oth Maeda, Yuichi oth Yamasaki, Eiji oth Tsushima, Hirofumi oth Igura, Takumi oth Himeno, Seiichi oth Seki, Kouichi oth Matsuzawa, Yuji oth in Journal of gastroenterology 1994 32(1997) vom: Jan., Seite 56-62 (DE-627)NLEJ188987215 (DE-600)1473159-9 1435-5922 nnns volume:32 year:1997 month:01 pages:56-62 extent:7 http://dx.doi.org/10.1007/BF01213297 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 32 1997 1 56-62 7 |
| allfields_unstemmed |
(DE-627)NLEJ207620601 DE-627 ger DE-627 rakwb eng Efficacy of combination therapy of interferon-α with ursodeoxycholic acid in chronic hepatitis C: A randomized controlled clinical trial 1997 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract The efficacy of interferon-α therapy in the treatment of chronic hepatitis C is still limited. A combination therapy of interferon-α with ursodeoxycholic acid (UDCA) was tested for its efficacy in the treatment of chronic hepatitis C by a randomized controlled study. Eighty consecutive Japanese patients with chronic hepatitis C were randomly divided into two groups: one group was treated with interferon-α (group A,n=40) and the other with a combination of interferon-α and UDCA (group B,n=40). In both groups, human interferon-α (6 million units per day) was intramuscularly injected daily for 2 weeks and then three times a week for 22 weeks: this 24-week period was followed by 24 weeks of observation. In group B, UDCA was also administered, daily at a dose of 600mg orally, from the beginning of the interferon therapy and administration was continued for 48 weeks. The rates for ALT normalization and clearance of hepatitis C virus (HCV) viremia at the end of the 24-week interferon therapy were similar for groups A and B (58% vs 60% and 55% vs 48%, respectively). At the end of the 24-week follow-up, the sustained normalization rates for ALT levels for the two groups were not different (35% vs 43%), while the rate of clearance was higher in group B (40%) than in group A (23%), but the difference was not significant (P=0.14). The sustained complete response, i.e., HCV RNA negativity at the end of the follow-up, as well as the maintenance of ALT normalization during the follow-up period, was more frequent in group B (38%) than in group A (18%) although the difference was not significantP=0.08). The rate of HCV reactivation after interferon was discontinued was significantly lower in group B (16%) than in group A (59%) (P<0.01). Although this combination therapy did not lead to a sufficiently sustained complete response, it could serve as adjuvant antiviral therapy when a suitable dosage and administration period are determined. Springer Online Journal Archives 1860-2002 Kiso, Shinichi oth Kawata, Sumio oth Tamura, Shinji oth Imai, Yasuharu oth Inui, Yoshiaki oth Nagase, Toshihiko oth Maeda, Yuichi oth Yamasaki, Eiji oth Tsushima, Hirofumi oth Igura, Takumi oth Himeno, Seiichi oth Seki, Kouichi oth Matsuzawa, Yuji oth in Journal of gastroenterology 1994 32(1997) vom: Jan., Seite 56-62 (DE-627)NLEJ188987215 (DE-600)1473159-9 1435-5922 nnns volume:32 year:1997 month:01 pages:56-62 extent:7 http://dx.doi.org/10.1007/BF01213297 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 32 1997 1 56-62 7 |
| allfieldsGer |
(DE-627)NLEJ207620601 DE-627 ger DE-627 rakwb eng Efficacy of combination therapy of interferon-α with ursodeoxycholic acid in chronic hepatitis C: A randomized controlled clinical trial 1997 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract The efficacy of interferon-α therapy in the treatment of chronic hepatitis C is still limited. A combination therapy of interferon-α with ursodeoxycholic acid (UDCA) was tested for its efficacy in the treatment of chronic hepatitis C by a randomized controlled study. Eighty consecutive Japanese patients with chronic hepatitis C were randomly divided into two groups: one group was treated with interferon-α (group A,n=40) and the other with a combination of interferon-α and UDCA (group B,n=40). In both groups, human interferon-α (6 million units per day) was intramuscularly injected daily for 2 weeks and then three times a week for 22 weeks: this 24-week period was followed by 24 weeks of observation. In group B, UDCA was also administered, daily at a dose of 600mg orally, from the beginning of the interferon therapy and administration was continued for 48 weeks. The rates for ALT normalization and clearance of hepatitis C virus (HCV) viremia at the end of the 24-week interferon therapy were similar for groups A and B (58% vs 60% and 55% vs 48%, respectively). At the end of the 24-week follow-up, the sustained normalization rates for ALT levels for the two groups were not different (35% vs 43%), while the rate of clearance was higher in group B (40%) than in group A (23%), but the difference was not significant (P=0.14). The sustained complete response, i.e., HCV RNA negativity at the end of the follow-up, as well as the maintenance of ALT normalization during the follow-up period, was more frequent in group B (38%) than in group A (18%) although the difference was not significantP=0.08). The rate of HCV reactivation after interferon was discontinued was significantly lower in group B (16%) than in group A (59%) (P<0.01). Although this combination therapy did not lead to a sufficiently sustained complete response, it could serve as adjuvant antiviral therapy when a suitable dosage and administration period are determined. Springer Online Journal Archives 1860-2002 Kiso, Shinichi oth Kawata, Sumio oth Tamura, Shinji oth Imai, Yasuharu oth Inui, Yoshiaki oth Nagase, Toshihiko oth Maeda, Yuichi oth Yamasaki, Eiji oth Tsushima, Hirofumi oth Igura, Takumi oth Himeno, Seiichi oth Seki, Kouichi oth Matsuzawa, Yuji oth in Journal of gastroenterology 1994 32(1997) vom: Jan., Seite 56-62 (DE-627)NLEJ188987215 (DE-600)1473159-9 1435-5922 nnns volume:32 year:1997 month:01 pages:56-62 extent:7 http://dx.doi.org/10.1007/BF01213297 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 32 1997 1 56-62 7 |
| allfieldsSound |
(DE-627)NLEJ207620601 DE-627 ger DE-627 rakwb eng Efficacy of combination therapy of interferon-α with ursodeoxycholic acid in chronic hepatitis C: A randomized controlled clinical trial 1997 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract The efficacy of interferon-α therapy in the treatment of chronic hepatitis C is still limited. A combination therapy of interferon-α with ursodeoxycholic acid (UDCA) was tested for its efficacy in the treatment of chronic hepatitis C by a randomized controlled study. Eighty consecutive Japanese patients with chronic hepatitis C were randomly divided into two groups: one group was treated with interferon-α (group A,n=40) and the other with a combination of interferon-α and UDCA (group B,n=40). In both groups, human interferon-α (6 million units per day) was intramuscularly injected daily for 2 weeks and then three times a week for 22 weeks: this 24-week period was followed by 24 weeks of observation. In group B, UDCA was also administered, daily at a dose of 600mg orally, from the beginning of the interferon therapy and administration was continued for 48 weeks. The rates for ALT normalization and clearance of hepatitis C virus (HCV) viremia at the end of the 24-week interferon therapy were similar for groups A and B (58% vs 60% and 55% vs 48%, respectively). At the end of the 24-week follow-up, the sustained normalization rates for ALT levels for the two groups were not different (35% vs 43%), while the rate of clearance was higher in group B (40%) than in group A (23%), but the difference was not significant (P=0.14). The sustained complete response, i.e., HCV RNA negativity at the end of the follow-up, as well as the maintenance of ALT normalization during the follow-up period, was more frequent in group B (38%) than in group A (18%) although the difference was not significantP=0.08). The rate of HCV reactivation after interferon was discontinued was significantly lower in group B (16%) than in group A (59%) (P<0.01). Although this combination therapy did not lead to a sufficiently sustained complete response, it could serve as adjuvant antiviral therapy when a suitable dosage and administration period are determined. Springer Online Journal Archives 1860-2002 Kiso, Shinichi oth Kawata, Sumio oth Tamura, Shinji oth Imai, Yasuharu oth Inui, Yoshiaki oth Nagase, Toshihiko oth Maeda, Yuichi oth Yamasaki, Eiji oth Tsushima, Hirofumi oth Igura, Takumi oth Himeno, Seiichi oth Seki, Kouichi oth Matsuzawa, Yuji oth in Journal of gastroenterology 1994 32(1997) vom: Jan., Seite 56-62 (DE-627)NLEJ188987215 (DE-600)1473159-9 1435-5922 nnns volume:32 year:1997 month:01 pages:56-62 extent:7 http://dx.doi.org/10.1007/BF01213297 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 32 1997 1 56-62 7 |
| language |
English |
| source |
in Journal of gastroenterology 32(1997) vom: Jan., Seite 56-62 volume:32 year:1997 month:01 pages:56-62 extent:7 |
| sourceStr |
in Journal of gastroenterology 32(1997) vom: Jan., Seite 56-62 volume:32 year:1997 month:01 pages:56-62 extent:7 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Journal of gastroenterology |
| authorswithroles_txt_mv |
Kiso, Shinichi @@oth@@ Kawata, Sumio @@oth@@ Tamura, Shinji @@oth@@ Imai, Yasuharu @@oth@@ Inui, Yoshiaki @@oth@@ Nagase, Toshihiko @@oth@@ Maeda, Yuichi @@oth@@ Yamasaki, Eiji @@oth@@ Tsushima, Hirofumi @@oth@@ Igura, Takumi @@oth@@ Himeno, Seiichi @@oth@@ Seki, Kouichi @@oth@@ Matsuzawa, Yuji @@oth@@ |
| publishDateDaySort_date |
1997-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188987215 |
| id |
NLEJ207620601 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ207620601</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210706233236.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1997 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ207620601</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Efficacy of combination therapy of interferon-α with ursodeoxycholic acid in chronic hepatitis C: A randomized controlled clinical trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1997</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The efficacy of interferon-α therapy in the treatment of chronic hepatitis C is still limited. A combination therapy of interferon-α with ursodeoxycholic acid (UDCA) was tested for its efficacy in the treatment of chronic hepatitis C by a randomized controlled study. Eighty consecutive Japanese patients with chronic hepatitis C were randomly divided into two groups: one group was treated with interferon-α (group A,n=40) and the other with a combination of interferon-α and UDCA (group B,n=40). In both groups, human interferon-α (6 million units per day) was intramuscularly injected daily for 2 weeks and then three times a week for 22 weeks: this 24-week period was followed by 24 weeks of observation. In group B, UDCA was also administered, daily at a dose of 600mg orally, from the beginning of the interferon therapy and administration was continued for 48 weeks. The rates for ALT normalization and clearance of hepatitis C virus (HCV) viremia at the end of the 24-week interferon therapy were similar for groups A and B (58% vs 60% and 55% vs 48%, respectively). At the end of the 24-week follow-up, the sustained normalization rates for ALT levels for the two groups were not different (35% vs 43%), while the rate of clearance was higher in group B (40%) than in group A (23%), but the difference was not significant (P=0.14). The sustained complete response, i.e., HCV RNA negativity at the end of the follow-up, as well as the maintenance of ALT normalization during the follow-up period, was more frequent in group B (38%) than in group A (18%) although the difference was not significantP=0.08). The rate of HCV reactivation after interferon was discontinued was significantly lower in group B (16%) than in group A (59%) (P<0.01). Although this combination therapy did not lead to a sufficiently sustained complete response, it could serve as adjuvant antiviral therapy when a suitable dosage and administration period are determined.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kiso, Shinichi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kawata, Sumio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tamura, Shinji</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Imai, Yasuharu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Inui, Yoshiaki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nagase, Toshihiko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maeda, Yuichi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamasaki, Eiji</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tsushima, Hirofumi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Igura, Takumi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Himeno, Seiichi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Seki, Kouichi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matsuzawa, Yuji</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Journal of gastroenterology</subfield><subfield code="d">1994</subfield><subfield code="g">32(1997) vom: Jan., Seite 56-62</subfield><subfield code="w">(DE-627)NLEJ188987215</subfield><subfield code="w">(DE-600)1473159-9</subfield><subfield code="x">1435-5922</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:32</subfield><subfield code="g">year:1997</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:56-62</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF01213297</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">32</subfield><subfield code="j">1997</subfield><subfield code="c">1</subfield><subfield code="h">56-62</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188987215 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1435-5922 |
| topic_title |
Efficacy of combination therapy of interferon-α with ursodeoxycholic acid in chronic hepatitis C: A randomized controlled clinical trial |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
s k sk s k sk s t st y i yi y i yi t n tn y m ym e y ey h t ht t i ti s h sh k s ks y m ym |
| hierarchy_parent_title |
Journal of gastroenterology |
| hierarchy_parent_id |
NLEJ188987215 |
| hierarchy_top_title |
Journal of gastroenterology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188987215 (DE-600)1473159-9 |
| title |
Efficacy of combination therapy of interferon-α with ursodeoxycholic acid in chronic hepatitis C: A randomized controlled clinical trial |
| spellingShingle |
Efficacy of combination therapy of interferon-α with ursodeoxycholic acid in chronic hepatitis C: A randomized controlled clinical trial |
| ctrlnum |
(DE-627)NLEJ207620601 |
| title_full |
Efficacy of combination therapy of interferon-α with ursodeoxycholic acid in chronic hepatitis C: A randomized controlled clinical trial |
| journal |
Journal of gastroenterology |
| journalStr |
Journal of gastroenterology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1997 |
| contenttype_str_mv |
zzz |
| container_start_page |
56 |
| container_volume |
32 |
| physical |
7 |
| format_se |
Elektronische Aufsätze |
| title_sort |
efficacy of combination therapy of interferon-α with ursodeoxycholic acid in chronic hepatitis c: a randomized controlled clinical trial |
| title_auth |
Efficacy of combination therapy of interferon-α with ursodeoxycholic acid in chronic hepatitis C: A randomized controlled clinical trial |
| abstract |
Abstract The efficacy of interferon-α therapy in the treatment of chronic hepatitis C is still limited. A combination therapy of interferon-α with ursodeoxycholic acid (UDCA) was tested for its efficacy in the treatment of chronic hepatitis C by a randomized controlled study. Eighty consecutive Japanese patients with chronic hepatitis C were randomly divided into two groups: one group was treated with interferon-α (group A,n=40) and the other with a combination of interferon-α and UDCA (group B,n=40). In both groups, human interferon-α (6 million units per day) was intramuscularly injected daily for 2 weeks and then three times a week for 22 weeks: this 24-week period was followed by 24 weeks of observation. In group B, UDCA was also administered, daily at a dose of 600mg orally, from the beginning of the interferon therapy and administration was continued for 48 weeks. The rates for ALT normalization and clearance of hepatitis C virus (HCV) viremia at the end of the 24-week interferon therapy were similar for groups A and B (58% vs 60% and 55% vs 48%, respectively). At the end of the 24-week follow-up, the sustained normalization rates for ALT levels for the two groups were not different (35% vs 43%), while the rate of clearance was higher in group B (40%) than in group A (23%), but the difference was not significant (P=0.14). The sustained complete response, i.e., HCV RNA negativity at the end of the follow-up, as well as the maintenance of ALT normalization during the follow-up period, was more frequent in group B (38%) than in group A (18%) although the difference was not significantP=0.08). The rate of HCV reactivation after interferon was discontinued was significantly lower in group B (16%) than in group A (59%) (P<0.01). Although this combination therapy did not lead to a sufficiently sustained complete response, it could serve as adjuvant antiviral therapy when a suitable dosage and administration period are determined. |
| abstractGer |
Abstract The efficacy of interferon-α therapy in the treatment of chronic hepatitis C is still limited. A combination therapy of interferon-α with ursodeoxycholic acid (UDCA) was tested for its efficacy in the treatment of chronic hepatitis C by a randomized controlled study. Eighty consecutive Japanese patients with chronic hepatitis C were randomly divided into two groups: one group was treated with interferon-α (group A,n=40) and the other with a combination of interferon-α and UDCA (group B,n=40). In both groups, human interferon-α (6 million units per day) was intramuscularly injected daily for 2 weeks and then three times a week for 22 weeks: this 24-week period was followed by 24 weeks of observation. In group B, UDCA was also administered, daily at a dose of 600mg orally, from the beginning of the interferon therapy and administration was continued for 48 weeks. The rates for ALT normalization and clearance of hepatitis C virus (HCV) viremia at the end of the 24-week interferon therapy were similar for groups A and B (58% vs 60% and 55% vs 48%, respectively). At the end of the 24-week follow-up, the sustained normalization rates for ALT levels for the two groups were not different (35% vs 43%), while the rate of clearance was higher in group B (40%) than in group A (23%), but the difference was not significant (P=0.14). The sustained complete response, i.e., HCV RNA negativity at the end of the follow-up, as well as the maintenance of ALT normalization during the follow-up period, was more frequent in group B (38%) than in group A (18%) although the difference was not significantP=0.08). The rate of HCV reactivation after interferon was discontinued was significantly lower in group B (16%) than in group A (59%) (P<0.01). Although this combination therapy did not lead to a sufficiently sustained complete response, it could serve as adjuvant antiviral therapy when a suitable dosage and administration period are determined. |
| abstract_unstemmed |
Abstract The efficacy of interferon-α therapy in the treatment of chronic hepatitis C is still limited. A combination therapy of interferon-α with ursodeoxycholic acid (UDCA) was tested for its efficacy in the treatment of chronic hepatitis C by a randomized controlled study. Eighty consecutive Japanese patients with chronic hepatitis C were randomly divided into two groups: one group was treated with interferon-α (group A,n=40) and the other with a combination of interferon-α and UDCA (group B,n=40). In both groups, human interferon-α (6 million units per day) was intramuscularly injected daily for 2 weeks and then three times a week for 22 weeks: this 24-week period was followed by 24 weeks of observation. In group B, UDCA was also administered, daily at a dose of 600mg orally, from the beginning of the interferon therapy and administration was continued for 48 weeks. The rates for ALT normalization and clearance of hepatitis C virus (HCV) viremia at the end of the 24-week interferon therapy were similar for groups A and B (58% vs 60% and 55% vs 48%, respectively). At the end of the 24-week follow-up, the sustained normalization rates for ALT levels for the two groups were not different (35% vs 43%), while the rate of clearance was higher in group B (40%) than in group A (23%), but the difference was not significant (P=0.14). The sustained complete response, i.e., HCV RNA negativity at the end of the follow-up, as well as the maintenance of ALT normalization during the follow-up period, was more frequent in group B (38%) than in group A (18%) although the difference was not significantP=0.08). The rate of HCV reactivation after interferon was discontinued was significantly lower in group B (16%) than in group A (59%) (P<0.01). Although this combination therapy did not lead to a sufficiently sustained complete response, it could serve as adjuvant antiviral therapy when a suitable dosage and administration period are determined. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Efficacy of combination therapy of interferon-α with ursodeoxycholic acid in chronic hepatitis C: A randomized controlled clinical trial |
| url |
http://dx.doi.org/10.1007/BF01213297 |
| remote_bool |
true |
| author2 |
Kiso, Shinichi Kawata, Sumio Tamura, Shinji Imai, Yasuharu Inui, Yoshiaki Nagase, Toshihiko Maeda, Yuichi Yamasaki, Eiji Tsushima, Hirofumi Igura, Takumi Himeno, Seiichi Seki, Kouichi Matsuzawa, Yuji |
| author2Str |
Kiso, Shinichi Kawata, Sumio Tamura, Shinji Imai, Yasuharu Inui, Yoshiaki Nagase, Toshihiko Maeda, Yuichi Yamasaki, Eiji Tsushima, Hirofumi Igura, Takumi Himeno, Seiichi Seki, Kouichi Matsuzawa, Yuji |
| ppnlink |
NLEJ188987215 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth |
| up_date |
2024-07-06T10:11:51.533Z |
| _version_ |
1803824095856427008 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ207620601</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210706233236.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1997 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ207620601</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Efficacy of combination therapy of interferon-α with ursodeoxycholic acid in chronic hepatitis C: A randomized controlled clinical trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1997</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The efficacy of interferon-α therapy in the treatment of chronic hepatitis C is still limited. A combination therapy of interferon-α with ursodeoxycholic acid (UDCA) was tested for its efficacy in the treatment of chronic hepatitis C by a randomized controlled study. Eighty consecutive Japanese patients with chronic hepatitis C were randomly divided into two groups: one group was treated with interferon-α (group A,n=40) and the other with a combination of interferon-α and UDCA (group B,n=40). In both groups, human interferon-α (6 million units per day) was intramuscularly injected daily for 2 weeks and then three times a week for 22 weeks: this 24-week period was followed by 24 weeks of observation. In group B, UDCA was also administered, daily at a dose of 600mg orally, from the beginning of the interferon therapy and administration was continued for 48 weeks. The rates for ALT normalization and clearance of hepatitis C virus (HCV) viremia at the end of the 24-week interferon therapy were similar for groups A and B (58% vs 60% and 55% vs 48%, respectively). At the end of the 24-week follow-up, the sustained normalization rates for ALT levels for the two groups were not different (35% vs 43%), while the rate of clearance was higher in group B (40%) than in group A (23%), but the difference was not significant (P=0.14). The sustained complete response, i.e., HCV RNA negativity at the end of the follow-up, as well as the maintenance of ALT normalization during the follow-up period, was more frequent in group B (38%) than in group A (18%) although the difference was not significantP=0.08). The rate of HCV reactivation after interferon was discontinued was significantly lower in group B (16%) than in group A (59%) (P<0.01). Although this combination therapy did not lead to a sufficiently sustained complete response, it could serve as adjuvant antiviral therapy when a suitable dosage and administration period are determined.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kiso, Shinichi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kawata, Sumio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tamura, Shinji</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Imai, Yasuharu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Inui, Yoshiaki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nagase, Toshihiko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maeda, Yuichi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamasaki, Eiji</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tsushima, Hirofumi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Igura, Takumi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Himeno, Seiichi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Seki, Kouichi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matsuzawa, Yuji</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Journal of gastroenterology</subfield><subfield code="d">1994</subfield><subfield code="g">32(1997) vom: Jan., Seite 56-62</subfield><subfield code="w">(DE-627)NLEJ188987215</subfield><subfield code="w">(DE-600)1473159-9</subfield><subfield code="x">1435-5922</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:32</subfield><subfield code="g">year:1997</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:56-62</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF01213297</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">32</subfield><subfield code="j">1997</subfield><subfield code="c">1</subfield><subfield code="h">56-62</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
| score |
7.401374 |